Ipsilateral lung dose as a correlative measure for radiation pneumonitis in patients treated with definitive concurrent radiochemotherapy

被引:1
作者
Kirakli, Esra Korkmaz [1 ]
Erdem, Sevilay [1 ]
Susam, Seher [2 ]
Erim, Eser [1 ]
机构
[1] Dr Suat Seren Chest Dis & Surg Res & Training Hos, Dept Radiat, Izmir, Turkiye
[2] Dr Suat Seren Chest Dis & Surg Res & Training Hos, Dept Radiol, Izmir, Turkiye
关键词
Ipsilateral lung dose; nonsmall cell lung cancer; radiation pneumonitis; radiochemotherapy; VOLUME HISTOGRAM PARAMETERS; REGIONAL DIFFERENCES; CANCER PATIENTS; PHASE-II; RADIOTHERAPY; TOXICITY; THERAPY; CHEMORADIATION; PREDICTION; CRITERIA;
D O I
10.4103/jcrt.jcrt_618_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Mean lung dose (MLD) and percent of total lung (TL) volume that receive a dose greater than 20 Gy (V-20) have been the most validated parameters in the prediction of radiation pneumonitis (RP). However, these parameters present mean values of TL parenchyma and predict the right and the left lung as a unique functional organ unit, not take into account the difference in function and dose density between the lungs. Furthermore, there have been very limited data evaluating ipsilateral lung dosimetric constraints in addition to TL parameters to predict RP in non-small cell lung cancer (NSCLC) patients treated with radiochemotherapy (RCT). Methods: Between 2010 and 2017, clinical-radiological findings of NSCLC patients treated with RCT were evaluated in terms of RP, retrospectively. MLD, V-20, and V-30 values of ipsilateral lung were assessed from dose-volume histogram and registered. The primary endpoint was to assess the relation between ipsilateral lung dose constraints and RP risk. Results: There were 75 patients. There was >= Grade 2 RP in 33 cases (%44). In univariate analysis, ipsilateral MLD, ipsilateral V-20, ipsilateral V-30,V- and TL V-30 were found to be significant. Ipsilateral MLD and PTV were found to be the independent risk factors for RP. Cutoff values for RP risk were determined as 18Gy, 35%, and 28% for ipsilateral MLD, ipsilateral V-20, and ipsilateral V-30, respectively. Predictive values for ipsilateral MLD and ipsilateral V-20 were higher than TL. Conclusions: In NSCLC patients treated with RCT, MLD, V-20, and V-30 values of ipsilateral lung parameters might increase the predictability of RP risk in addition to TL parameters. Advances in Knowledge: Cutoff values for RP risk were determined as 18Gy, 35%, and 28% for ipsilateral MLD, ipsilateral V-20, and ipsilateral V-30, respectively. Predictive values for ipsilateral MLD and ipsilateral V-20 were higher than TL.
引用
收藏
页码:2023 / 1159
页数:7
相关论文
共 50 条
  • [21] Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
    Wang, Dongqing
    Zhu, Jingyu
    Sun, Jinbo
    Li, Baosheng
    Wang, Zhongtang
    Wei, Ling
    Yin, Yong
    Sun, Hongfu
    Fu, Zheng
    Zhang, Xingguo
    Huo, Zongwei
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (12) : 943 - 952
  • [22] The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation
    Ren, Chengbo
    Ji, Tianlong
    Liu, Tingting
    Dang, Jun
    Li, Guang
    RADIATION ONCOLOGY, 2018, 13
  • [23] High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy
    Shen, Tianle
    Sheng, Liming
    Chen, Ying
    Cheng, Lei
    Du, Xianghui
    JOURNAL OF RADIATION RESEARCH, 2020, 61 (01) : 117 - 122
  • [24] Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer
    Ogata, Takeshi
    Katsui, Kuniaki
    Yoshio, Kotaro
    Ihara, Hiroki
    Katayama, Norihisa
    Soh, Junichi
    Kuroda, Masahiro
    Kiura, Katsuyuki
    Maeda, Yoshinobu
    Toyooka, Shinichi
    Kanazawa, Susumu
    ACTA MEDICA OKAYAMA, 2018, 72 (05) : 507 - 513
  • [25] Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy
    Isoyama, Shoko
    Yamaguchi, Kakuhiro
    Imano, Nobuki
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Miyamoto, Shintaro
    Nakashima, Taku
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Hamada, Hironobu
    Nagata, Yasushi
    Hattori, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (11) : 1698 - 1705
  • [26] Radiation pneumonitis in non-small-cell lung cancer patients treated with helical tomotherapy
    Yao, B.
    Wang, Y. D.
    Liu, Q. Z.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2016, 19 (01) : 25 - 29
  • [27] Cytokine Profiles of Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy with Regards to Radiation Pneumonitis Severity
    Jeong, Bae Kwon
    Kim, Jin Hyun
    Jung, Myeong Hee
    Kang, Ki Mun
    Lee, Yun Hee
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 10
  • [28] External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy
    Niezink, Anne G. H.
    van der Schaaf, Arjen
    Wijsman, Robin
    Chouvalova, Olga
    van der Wekken, Anthonie J.
    Rutgers, Steven R.
    Pieterman, Remge M.
    van Putten, John W. G.
    Hosson, Sander M. de
    van der Leest, Annija H. D.
    Ubbels, Jan F.
    Woltman-van Iersel, Marleen
    Widder, Joachim
    Langendijk, Johannes A.
    Muijs, Christina
    RADIOTHERAPY AND ONCOLOGY, 2023, 186
  • [29] Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy
    Wu, Kan
    Xu, Xiao
    Li, Xiadong
    Wang, Jiahao
    Zhu, Lucheng
    Chen, Xueqin
    Wang, Bing
    Zhang, Minna
    Xia, Bing
    Ma, Shenglin
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6531 - 6539
  • [30] Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in Elderly Lung Cancer Patients
    Rades, Dirk
    Cremers, Florian
    Janssen, Stefan
    Bartscht, Tobias
    Kristiansen, Charlotte
    Timke, Carmen
    Duma, Marciana n.
    Yu, Nathan y.
    Bohnet, Sabine
    ANTICANCER RESEARCH, 2024, 44 (05) : 2073 - 2079